NYSE:OGN
Organon & Co.
A leading biopharma firm focused on delivering innovative treatments for women's health, men's sexual dysfunction, and neuroscience with a strong digital health ecosystem.
Key Metrics
Investment Thesis
Bull Case
Organon possesses a differentiated product pipeline in high-growth areas like women's health and men's sexual dysfunction with strong recurring revenue potential from digital health subscriptions. The company's positive operating cash flow of $700M provides a foundation to service its debt load if earnings stabilize. Strategic focus on patient-centric digital solutions could unlock new value streams and improve long-term stickiness in competitive markets.
Bear Case
The sharp decline in net income from 2024 to 2025 signals deteriorating operational efficiency or one-off losses that warrant caution. The company's balance sheet is heavily leveraged with $8.63B in long-term debt, leaving little room for error during economic downturns. High interest expenses and significant cash outflows from other financing activities suggest ongoing financial strain that could limit R&D investment capabilities.
About Organon & Co.
Organon & Co. (NYSE: OGN) is a global biopharmaceutical company specializing in the development and commercialization of innovative medicines primarily for women's health, men's sexual dysfunction, and neuroscience. The company serves markets across the United States, Europe, and emerging economies through its strategic focus on digital health platforms and proprietary therapeutics.
Analysis
Management Discussion
Despite generating $700M in operating cash flow, net income dropped sharply to $187M in 2025 from $864M the prior year, indicating margin compression or non-recurring charges. Heavy debt issuances of $1.05B contrasted with significant repayments of $1.51B, while other financing activities resulted in a massive outflow of $3.22B, suggesting active balance sheet restructuring. Revenue remained relatively stable at $6.22B, but the cost of revenue surged to $2.90B, impacting gross profit margins.
Industry Overview
The global biopharmaceutical industry is currently navigating post-pandemic normalization with a renewed focus on digital therapeutics and personalized medicine. Competition in women's health and men's sexual dysfunction remains intense, with incumbents facing pressure from generic entrants and biosimilar innovations. Regulatory bodies are increasingly scrutinizing the efficacy claims of digital health tools integrated into traditional pharmaceutical offerings.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $6.17B | $6.26B | $6.40B | $6.22B |
| Cost of Revenue | $2.29B | $2.52B | $2.69B | $2.90B |
| Gross Profit | $3.88B | $3.75B | $3.71B | $3.31B |
| Operating Expenses | $2.76B | $3.08B | $2.91B | $2.89B |
| Operating Income | $1.12B | $673.0M | $807.0M | $425.0M |
| G&A | $1.70B | $1.89B | $1.76B | $1.72B |
| Stock-Based Comp | $75.0M | $101.0M | $105.0M | $77.0M |
| Depreciation | $96.0M | $120.0M | $132.0M | $156.0M |
| Amortization | $116.0M | $116.0M | $145.0M | $205.0M |
| Other OpEx | $1.05B | $1.18B | $1.15B | $1.17B |
| Non-Operating Income | $0 | $0 | $0 | $0 |
| Interest Expense | $422.0M | $527.0M | $520.0M | $504.0M |
| Pre-Tax Income | $1.12B | $673.0M | $807.0M | $425.0M |
| Income Tax | $205.0M | $-350.0M | $-57.0M | $238.0M |
| Continuing Ops | $917.0M | $1.02B | $864.0M | $187.0M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $917.0M | $1.02B | $864.0M | $187.0M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $917.0M | $1.02B | $864.0M | $187.0M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $3.93B | $4.51B | $4.35B | $4.35B |
| Cash & Equivalents | $706.0M | $693.0M | $675.0M | $574.0M |
| Accounts Receivable | $1.48B | $1.74B | $1.36B | $1.33B |
| Inventory | $1.00B | $1.31B | $1.32B | $1.41B |
| Other Current Assets | $747.0M | $756.0M | $994.0M | $1.04B |
| Long-Term Assets | $7.02B | $7.55B | $8.75B | $8.52B |
| PP&E (Net) | $1.02B | $1.18B | $1.17B | $1.30B |
| Intangibles | — | — | — | $1.13B |
| Goodwill | $4.60B | $4.60B | $4.68B | $4.15B |
| Operating Leases | $215.0M | $173.0M | $157.0M | $155.0M |
| Other LT Assets | $1.19B | $1.59B | $2.75B | $1.77B |
| Total Assets | $10.96B | $12.06B | $13.10B | $12.87B |
| Current Liabilities | $2.51B | $2.92B | $2.72B | $2.39B |
| Accounts Payable | $1.13B | $1.31B | $1.15B | $952.0M |
| Current Debt | $8.0M | $9.0M | $20.0M | — |
| Current Leases | $49.0M | $46.0M | $44.0M | $40.0M |
| Taxes Payable | $184.0M | $206.0M | $134.0M | $85.0M |
| Other Current Liab | $1.14B | $1.34B | $1.37B | $1.31B |
| Long-Term Liabilities | $9.34B | $9.21B | $9.91B | $9.72B |
| Long-Term Debt | $8.90B | $8.75B | $8.86B | $8.63B |
| LT Operating Leases | $150.0M | $125.0M | $112.0M | $116.0M |
| Other LT Liab | $280.0M | $334.0M | $939.0M | $981.0M |
| Total Liabilities | $11.85B | $12.13B | $12.63B | $12.12B |
| Shareholders' Equity | $-892.0M | $-70.0M | $472.0M | $752.0M |
| Retained Earnings | $-331.0M | $443.0M | $1.01B | $1.11B |
| AOCI | $-564.0M | $-541.0M | $-649.0M | $-527.0M |
| Total L&E | $10.96B | $12.06B | $13.10B | $12.87B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $917.0M | $1.02B | $864.0M | $187.0M |
| Non-Cash Adjustments | $-395.0M | $-941.0M | $443.0M | $1.11B |
| Working Capital Changes | $336.0M | $717.0M | $-368.0M | $-593.0M |
| Cash from Operations | $858.0M | $799.0M | $939.0M | $700.0M |
| Capital Expenditures | $196.0M | $251.0M | $175.0M | $162.0M |
| Cash from Investing | $-420.0M | $-260.0M | $-513.0M | $-390.0M |
| Debt Issuances | $0 | $80.0M | $1.19B | $1.05B |
| Debt Repayments | $108.0M | $338.0M | $1.20B | $1.51B |
| Dividends Paid | $290.0M | $294.0M | $297.0M | $88.0M |
| Cash from Financing | $-433.0M | $-569.0M | $-368.0M | $-561.0M |
| FX Effect | $-36.0M | $17.0M | $-76.0M | $150.0M |
| Net Change in Cash | $-31.0M | $-13.0M | $-18.0M | $-101.0M |
| Beginning Cash | $737.0M | $706.0M | $693.0M | $675.0M |
| Ending Cash | $706.0M | $693.0M | $675.0M | $574.0M |
Frequently Asked Questions
How does Organon & Co. make money?
The company operates primarily through three key segments: Women's Health (including contraception, menopausal hormone therapy, and urogynecology), Men's Sexual Dysfunction (focusing on erectile dysfunction and testosterone therapies), and Neuroscience (targeting conditions like insomnia and depression).
What are the main risks for OGN?
High interest expense of $504M poses a significant drag on profitability amidst elevated borrowing costs. The company carries substantial long-term debt of $8.63B, creating liquidity pressure if cash flows weaken. Potential regulatory scrutiny on digital health tools and changing reimbursement landscapes for men's health products could impact future revenue growth.
What is OGN's competitive advantage?
Organon holds a robust portfolio of first-in-class and best-in-class products with strong patent protection in women's health. The company leverages its proprietary digital health platform, Organon Health Management Platform, to enhance patient adherence and real-world data collection. Significant goodwill assets reflect past acquisitions that expanded its therapeutic reach and commercial capabilities.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.